Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Gemcitabine + GP-2250 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GP-2250 | GP 2250|GP2250|substance 2250 | GP-2250 is an analog of Taurultam that induces reactive oxygen species (ROS) production, potentially resulting in reduced cell viability and proliferation, increased apoptosis, and inhibition of tumor growth (PMID: 28340556). | ||
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03854110 | Phase Ib/II | Gemcitabine + GP-2250 GP-2250 | Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine | Recruiting | USA | 0 |